Diazadispiroalkane Derivatives Are New Viral Entry Inhibitors-Reference-Cited by-同舟云学术

Diazadispiroalkane Derivatives Are New Viral Entry Inhibitors

Published:2021-03-18 Issue:4 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Adfeldt Rebekka¹,Schmitz Janna¹,Kropff Barbara²,Thomas Marco²^ORCID,Monakhova Natalia³,Hölper Julia E.⁴,Klupp Barbara G.⁴,Mettenleiter Thomas C.⁴,Makarov Vadim³,Bogner Elke¹^ORCID

Affiliation:

1. Charité-Universitätsmedizin Berlin, Institute of Virology, Berlin, Germany

2. Universitätsklinikum Erlangen, Institute of Clinical and Molecular Virology, Erlangen, Germany

3. FRC Fundamentals of Biotechnology, Russian Academy of Science, Moscow, Russia

4. Federal Research Institute for Animal Health, Friedrich-Loeffler-Institut, Griefswald, Germany

Abstract

Herpesviruses are widespread and can cause serious illness. Many currently available antiviral drugs have limited effects, result in rapid development of resistance, and often exhibit dose-dependent toxicity.

Funder

Forschungsfoerderung of the Charité

Sonnenfeld Stiftung

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02103-20

Reference40 articles.

1. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience

2. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy